Weight Loss Drug: Blindness Risk – EU Warning
- The European Medicines Agency (EMA) has concluded that semaglutide medications, including Ozempic, Wegovy and Rybelsus, may elevate the risk of a rare eye condition known as non-arteritic anterior...
- The review, initiated in January 2025, analyzed clinical trial data, post-marketing surveillance and medical literature.
- NAION is the second most common cause of optic nerve-related blindness after glaucoma.
Semaglutide Drugs (Ozempic, Wegovy) Linked to Vision Loss in EMA Review
Updated June 7, 2025
The European Medicines Agency (EMA) has concluded that semaglutide medications, including Ozempic, Wegovy and Rybelsus, may elevate the risk of a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to sudden vision loss.The EMA’s Pharmacovigilance Risk Assessment Commitee (PRAC) resolute that NAION should be listed as a “very rare” side effect of semaglutide.
The review, initiated in January 2025, analyzed clinical trial data, post-marketing surveillance and medical literature. Findings suggest that adults with type 2 diabetes taking semaglutide have approximately twice the risk of developing NAION compared to those not on the medication. The “very rare” classification means the condition could affect up to 1 in 10,000 users of the weight-loss drug.
NAION is the second most common cause of optic nerve-related blindness after glaucoma. The agency advises patients on semaglutide experiencing sudden vision loss or worsening eyesight to seek immediate medical attention. If diagnosed with NAION, patients should discontinue the medication.
Semaglutide, a GLP-1 receptor agonist, is patented by Novo Nordisk. It is prescribed for managing type 2 diabetes and obesity by enhancing insulin secretion and promoting satiety, aiding in blood sugar control and weight management.
recent studies also suggest that Ozempic and similar medications may increase the risk of kidney cancer. Though, these drugs may also lower the risk of more than a dozen other cancers, suggesting their overall benefit may still outweigh the hazards. The EMA previously investigated reports of suicidal thoughts associated with semaglutide use, though a definitive causal link was not established.
What’s next
The EMA’s recommendations will be reviewed by the Committee for Medicinal Products for Human Use (CHMP) before the European Commission makes a final decision. Novo Nordisk has affirmed its commitment to patient safety and is collaborating with the EMA to update product labels accordingly.